| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
43 |
| Employees |
390 |
| Revenues (TTM) (Millions $) |
293 |
| Net Income (TTM) (Millions $) |
-1,018 |
| Cash Flow (TTM) (Millions $) |
960 |
| Capital Exp. (TTM) (Millions $) |
22 |
Business Description
Zealand Pharma A is a biotechnology company headquartered in Copenhagen, Denmark. The company was founded in 1998 and is listed on the NASDAQ Copenhagen stock exchange. Zealand Pharma A specializes in the discovery, design, and development of innovative peptide-based medicines.
The company's focus is on targeting the secretion and signaling events of incretin hormones, which are critical in the regulation of glucose homeostasis and appetite. Their research efforts are focused on developing new treatments for metabolic disorders, such as type 2 diabetes, obesity, and gastrointestinal disorders.
Zealand Pharma A has a number of proprietary peptide drug candidates, including glepaglutide, which is being developed for the treatment of short bowel syndrome, and dasiglucagon, which is being developed for the treatment of severe hypoglycemia. The company has a number of other products in various stages of clinical development.
The development process of Zealand Pharma A's drugs involves a collaborative approach with its partners and stakeholders. The company has partnerships and collaborations with various leading pharmaceutical companies, including Boehringer Ingelheim, Sanofi, Eli Lilly, and Roche.
Zealand Pharma A employs over 150 people and has research and development facilities in Denmark and the United States. The company's revenue streams come from research and development collaborations, partnership agreements, and licensing agreements. As of December 2020, the company's market capitalization was around DKK 13 billion.
Company Address: Sydmarken 11 Copenhagen 2860
Company Phone Number: 88 77 36 00 Stock Exchange / Ticker: NASDAQ ZEAL
|
%
55.69%